Compumedics (ASX:CMP) Returns to FY2026 Profit as Revenue Reaches AUD 60.3 Million

Aditi Sarkar

30 September 2026 03:03 PM AEST

Compumedics (ASX:CMP) Returns to FY2026 Profit as Revenue Reaches AUD 60.3 Million

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Compumedics increased FY2026 Revenue to AUD 60.3 million from AUD 50.8 million.
EBITDA rose to AUD 5.4 million and the company returned to net profit.
Somfit and NEXUS 360 SaaS revenue reached AUD 10.2 million.
Open orders entering FY2027 totalled AUD 28.3 million, including AUD 13.1 million of MEG orders.

Compumedics Limited (ASX:CMP) closed FY2026 with higher revenue, improved EBITDA and a return to net profit. Growth across Asia Pacific, software subscriptions and magnetoencephalography systems helped lift revenue to AUD 60.3 million, while Operating Cash Flow also moved higher.

Revenue and Earnings Move Higher

FY2026 revenue increased from AUD 50.8 million to AUD 60.3 million. EBITDA rose to AUD 5.4 million from AUD 3.1 million, while net profit after tax reached AUD 0.3 million compared with a AUD 1.3 million loss in FY2025. EBITDA Margin increased to 9% from 6%, although gross margin declined to 51% from 55%.

Asia Pacific Leads the Expansion

Asia Pacific revenue reached AUD 36.497 million from AUD 22.435 million and generated a segment result of AUD 6.995 million. US revenue was AUD 16.362 million and Europe contributed AUD 7.395 million. The company also reduced sales and Marketing expense to AUD 14.7 million while reporting a AUD 2 million cost-savings programme.

Software and MEG Add New Revenue Streams

Somfit and NEXUS 360 SaaS platforms generated AUD 10.2 million, up from AUD 6.0 million, and represented 17% of group revenue. OrionMEG LifeSpan contributed AUD 9.7 million in its first year of revenue. Recurring Revenue reached AUD 18.3 million, equal to 30% of group revenue.

Cash Flow and Orders Enter FY2027

Operating cash inflow increased to AUD 6.6 million from AUD 0.4 million. Cash and equivalents stood at AUD 6.1 million, while the company reported a net cash position of AUD 5.6 million. FY2026 sales orders totalled AUD 62.7 million, with AUD 28.3 million of open orders entering FY2027.

FY2027 Focus Turns to Growth

Compumedics enters FY2027 targeting double-digit revenue growth, faster EBITDA growth and expansion of Somfit and MEG, while regulatory clearance and commercial execution remain key milestones.

FAQs

Q: What revenue did Compumedics report for FY2026?

A: Compumedics reported FY2026 revenue of AUD 60.3 million.

Q: What was FY2026 EBITDA?

A: EBITDA was AUD 5.4 million, compared with AUD 3.1 million in FY2025.

Q: How much revenue came from Somfit and NEXUS 360?

A: The SaaS platforms generated AUD 10.2 million in FY2026.

Q: What open orders entered FY2027?

A: Open orders totalled AUD 28.3 million, including AUD 13.1 million of MEG orders.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.